Should I Buy CMMB? CMMB 2026 Analysis

Should You Buy Chemomab Therapeutics Ltd (CMMB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.510

1 Day change

52 Week Range

8.240

Analysis Updated At

2026/02/13

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Chemomab Therapeutics Ltd (CMMB) is not a good buy for a beginner, long-term investor at this time. The stock shows no strong technical or proprietary trading signals, lacks positive trading sentiment, and has weak financial performance. Additionally, there are no significant news catalysts or influential trading activity to support a bullish case.

Technical Analysis

The stock's technical indicators show bearish moving averages (SMA_200 > SMA_20 > SMA_5), suggesting a downtrend. The RSI is neutral at 36.465, and the MACD is positive but contracting. The stock is trading near its support level (S1: 1.454), with resistance levels at 1.576 and above. Overall, the technical outlook is weak.

Positive Catalysts

NULL identified. No recent news, no significant hedge fund or insider activity, and no congress trading data.

Neutral/Negative Catalysts

The stock has declined by 6.33% in the regular market session, and its financial performance shows significant deterioration, with net income dropping by -49.99% YoY and EPS down -100.00% YoY in Q3 2025.

Financial Performance

In Q3 2025, the company reported zero revenue growth, a net income loss of -$1,742,000 (down -49.99% YoY), and an EPS decline of -100.00% YoY. Gross margin remains at 0%. The financials indicate poor performance and lack of growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

2 Analyst Rating

Wall Street analysts forecast CMMB stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.510

Low

Averages

17.5

High

Current: 1.510

Low

Averages

17.5

High

Oppenheimer

Outperform

maintain

$10 -> $25

AI Analysis

2025-08-27

Reason

Oppenheimer

Price Target

$10 -> $25

AI Analysis

2025-08-27

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Chemomab Therapeutics to $25 from $10 and keeps an Outperform rating on the shares to reflect Q2 results and management's intent to advance nebokitug in primary sclerosing cholangitis solely based on a third-party partnership, licensing or other similar transaction. The firm, which notes that its raised target reflects the potential value it sees to shareholders under an M&A or licensing scenario, points out that it also accounts for the company's 4-to-1 reverse share split.

Oppenheimer

Jeff Jones

Outperform

downgrade

$11 -> $10

2025-05-16

Reason

Oppenheimer

Jeff Jones

Price Target

$11 -> $10

2025-05-16

downgrade

Outperform

Reason

Oppenheimer analyst Jeff Jones lowered the firm's price target on Chemomab Therapeutics to $10 from $11 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 financial results, highlighting recent updates, including regulatory feedback providing clear guidance on approvable endpoints for nebokitug in PSC, and recent positive 48 weeks SPRING OLE results.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CMMB

Unlock Now

CMMB Should I Buy

CMMB Should I Buy

Should You Buy Chemomab Therapeutics Ltd (CMMB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch